BOTHELL, Wash., Sept. 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. will be hosting an analyst and institutional investor day in New York City on Thursday, October 4, 2007 from 12:00 p.m. - 3:00 p.m. Eastern Time at the Westin New York at Times Square, on 270 West 43rd Street. The luncheon event will feature a presentation from Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer and Gordon Brandt, M.D., Executive Vice President, Clinical Research and Medical Affairs of Nastech as well as the following leading scientific experts:
-- Robert S. Lindsay, M.B.Ch.B., Ph.D., F.R.C.P., Chief of Internal Medicine, Helen Hayes Hospital and Director of its Clinical Research Center, and Professor of Clinical Medicine, Columbia University, will provide an overview of osteoporosis and give expert insight on the use of Parathyroid Hormone (PTH1-34) as a therapy for this disease. -- Zachary T. Bloomgarden, M.D., Clinical Professor, Medicine/Endocrinology Diabetes and Bone Disease, Department of Medicine, Mount Sinai Medical Center, will present on diabetes and discuss current treatment regimens for the disease as well as those being developed. -- Carl D. Novina, M.D., Ph.D., Assistant Professor, Cancer Immunology and AIDS, Dana-Farber Cancer Institute, and Assistant Professor, Department of Pathology, Harvard Medical School, will present on the emerging field of RNA interference (RNAi) and its potential application as a therapeutic.
“Nastech continues to make significant progress in its peptide and protein therapeutic programs utilizing our non-injectable drug delivery technology as well as the development of RNAi therapeutics and now has a strong pipeline of products in or preparing to initiate Phase II clinical trials,” stated Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer of Nastech. “For this year’s analyst and institutional investor day event, Nastech is pleased to have gathered leading experts in their respective fields to highlight three areas at the core of Nastech’s drug development. This event will also lend insight into Nastech’s technologies and business, as we continue to execute upon a strategy that we believe has the potential to deliver important therapies to patients while creating significant value for our shareholders.”
The invitation-only event will be webcast commencing at 12:30 p.m. Eastern Time. To access the live webcast for this conference, please log on to Nastech’s website at http://www.nastech.com approximately 15 minutes prior to the presentation in order to register and download any necessary software.
About Nastech
Nastech is a biopharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. Nastech and our collaboration partners are developing products for multiple therapeutic areas including osteoporosis, obesity, diabetes, autism, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at http://www.nastech.com.
Nastech Forward-Looking Statements
Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Nastech to obtain additional funding; (ii) the ability of Nastech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) Nastech’s and/or a partner’s ability to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) Nastech’s and/or a partner’s ability to obtain required governmental approvals; and (v) Nastech’s and/or a partner’s ability to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Nastech’s most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Nastech assumes no obligation to update and supplement forward-looking statements because of subsequent events.
Contacts: Nastech Ed Bell Director, Investor Relations (425) 908-3639 ir@nastech.com Russo Partners, LLC Matthew Haines (Investors/Media) (212) 845-4235
Nastech Pharmaceutical Company Inc.
CONTACT: Ed Bell, Director, Investor Relations of Nastech,+1-425-908-3639, ir@nastech.com; Matthew Haines of Russo Partners, LLC,+1-212-845-4235, for Nastech
Web site: http://www.nastech.com/
